Clinilabs LLC has added a new member to its top management team, appointing David Hagerman as chief financial officer (CFO) and promoting Jeanine Falinski to senior vice president of Commercial Development.

Hagerman has more than 25 years of financial leadership experience in the life sciences and IT sectors. As CFO, he will oversee all financial operations and play a key role in driving long-term strategic and financial performance. Before joining Clinilabs, Hagerman was CFO at X-Chem and held senior leadership roles at Charles River Laboratories and Parexel. He began his career at IBM, where he spent 16 years in progressively more senior financial roles.

“It is a pleasure to add Dave to our senior management team. He brings an incredible skill set to Clinilabs that aligns with our vision for growth and expansion,” Clinilabs President/CEO Dr. Gary Zammit said.

Falinski steps into her new role armed with more than 20 years of pharmaceutical industry experience. She originally joined Clinilabs in 2004 as manager of Subject Recruitment and has since held several leadership roles, including senior director of Marketing and Communications and senior director of Business Development. After gaining additional commercial development experience at Evolution Research Group and Artcraft Health, she returned to Clinilabs in 2019 to lead the company’s marketing efforts and is now expanding her role to manage the commercial team.

“Since assuming her latest leadership role, Jeanine has delivered tremendous value to our commercial organization,” Dr. Zammit stated. “Her strategic leadership has elevated our level of customer engagement and will continue to support our mission of delivering high-quality, timely, and cost-effective drug, device and technology development services to clients worldwide.”

Clinilabs is a global, full-service contract research organization focused exclusively on CNS drug, device, and technology development. With deep expertise in CNS, Clinilabs is dedicated to advancing therapies for psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS diseases. The company partners with pharmaceutical, biotechnology, medical device and technology companies to provide clinical development services from first-in-human through Phase 3 trials. Since 2000, Clinilabs has conducted more than 800 CNS clinical trials and contributed to the approval of 23 new therapies across 14 CNS indications.